Safety concerns prompt Ipsen to pull Tazverik from market
Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers. The decision follows the results of an ongoing phase 1b/3 trial, called SYMPHONY-1, which is looking at the …